Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.43 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | F12 | P00748 | 3/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | SPR | P35270 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24914458 | 0.84 | MTHFD2 (0.60) | MTHFD2MAPTF12PARP1TNKS2 | |
| SCHEMBL24914511 | 0.83 | MTHFD2 (0.41) | ADORA1MTHFD2ESR2NR1H2KDM4E | |
| SCHEMBL24914515 | 0.82 | NR1H2 (0.44) | ADORA1MTHFD2ESR2NR1H2KDM4E | |
| SCHEMBL32660187 | 0.80 | ESR2 (0.46) | MTHFD2ESR2NR1H2F12PARP1 | |
| SCHEMBL31164770 | 0.80 | ESR2 (0.46) | MTHFD2ESR2NR1H2F12PARP1 | |
| SCHEMBL24914674 | 0.80 | MAPT (0.45) | ADORA1MTHFD2ESR2NR1H2KDM4E | |
| SCHEMBL24914388 | 0.76 | DDB1 (0.52) | MTHFD2MAPTF12PARP1TNKS2 | |
| SCHEMBL24914501 | 0.76 | KIT (0.42) | ADORA1ESR2NR1H2KDM4EMAPT | |
| SCHEMBL23580395 | 0.75 | ESR2 (0.42) | ADORA1ESR2NR1H2F12PARP1 | |
| SCHEMBL24914504 | 0.74 | MKNK1 (0.42) | ADORA1ESR2NR1H2KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327408-A1 | COMPOUNDS CONTAINING TETRAHYDRONAPHTHYRIDINONE OR TETRAHYDROPYRIDOPYRIMIDINONE SKELETON, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2024-10-03 | — | — | US | disclosed |
| WO-2023284807-A1 | COMPOUND CONTAINING TETRAHYDRONAPHTHYRIDONE OR TETRAHYDROPYRIDOPYRIMIDINONE SKELETON, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 中国药科大学 | 2023-01-19 | — | — | WO | disclosed |
| WO-2023284807-A1 | COMPOUND CONTAINING TETRAHYDRONAPHTHYRIDONE OR TETRAHYDROPYRIDOPYRIMIDINONE SKELETON, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 中国药科大学 | 2023-01-19 | — | — | WO | disclosed |
| CN-115611896-A | Compound containing tetralone or tetrahydropyridopyrimidone skeleton and preparation method and pharmaceutical application thereof | 中国药科大学 | 2023-01-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327408-A1 | COMPOUNDS CONTAINING TETRAHYDRONAPHTHYRIDINONE OR TETRAHYDROPYRIDOPYRIMIDINONE SKELETON, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | PRCP, TMPRSS15, WEE1 | ADORA1 1953/4885MTHFD2 1824/4885ESR2 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.